197 related articles for article (PubMed ID: 32488056)
1. Characterization of a new small-molecule inhibitor of HDAC6 in glioblastoma.
Auzmendi-Iriarte J; Saenz-Antoñanzas A; Mikelez-Alonso I; Carrasco-Garcia E; Tellaetxe-Abete M; Lawrie CH; Sampron N; Cortajarena AL; Matheu A
Cell Death Dis; 2020 Jun; 11(6):417. PubMed ID: 32488056
[TBL] [Abstract][Full Text] [Related]
2. High-selective HDAC6 inhibitor promotes HDAC6 degradation following autophagy modulation and enhanced antitumor immunity in glioblastoma.
Liu JR; Yu CW; Hung PY; Hsin LW; Chern JW
Biochem Pharmacol; 2019 May; 163():458-471. PubMed ID: 30885763
[TBL] [Abstract][Full Text] [Related]
3. Temozolomide-resistant Glioblastoma Depends on HDAC6 Activity Through Regulation of DNA Mismatch Repair.
Kim GW; Lee DH; Yeon SK; Jeon YH; Yoo J; Lee SW; Kwon SH
Anticancer Res; 2019 Dec; 39(12):6731-6741. PubMed ID: 31810938
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase 6 promotes growth of glioblastoma through the MKK7/JNK/c-Jun signaling pathway.
Huang Z; Xia Y; Hu K; Zeng S; Wu L; Liu S; Zhi C; Lai M; Chen D; Xie L; Yuan Z
J Neurochem; 2020 Jan; 152(2):221-234. PubMed ID: 31390677
[TBL] [Abstract][Full Text] [Related]
5. Tubastatin A, an inhibitor of HDAC6, enhances temozolomide‑induced apoptosis and reverses the malignant phenotype of glioblastoma cells.
Urdiciain A; Erausquin E; Meléndez B; Rey JA; Idoate MA; Castresana JS
Int J Oncol; 2019 May; 54(5):1797-1808. PubMed ID: 30864703
[TBL] [Abstract][Full Text] [Related]
6. Selective pharmacological inhibitors of HDAC6 reveal biochemical activity but functional tolerance in cancer models.
Depetter Y; Geurs S; De Vreese R; Goethals S; Vandoorn E; Laevens A; Steenbrugge J; Meyer E; de Tullio P; Bracke M; D'hooghe M; De Wever O
Int J Cancer; 2019 Aug; 145(3):735-747. PubMed ID: 30694564
[TBL] [Abstract][Full Text] [Related]
7. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
Negmeldin AT; Knoff JR; Pflum MKH
Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase 6 acts upstream of DNA damage response activation to support the survival of glioblastoma cells.
Yang WB; Wu AC; Hsu TI; Liou JP; Lo WL; Chang KY; Chen PY; Kikkawa U; Yang ST; Kao TJ; Chen RM; Chang WC; Ko CY; Chuang JY
Cell Death Dis; 2021 Sep; 12(10):884. PubMed ID: 34584069
[TBL] [Abstract][Full Text] [Related]
9. HDAC6 inhibition induces glioma stem cells differentiation and enhances cellular radiation sensitivity through the SHH/Gli1 signaling pathway.
Yang W; Liu Y; Gao R; Yu H; Sun T
Cancer Lett; 2018 Feb; 415():164-176. PubMed ID: 29222038
[TBL] [Abstract][Full Text] [Related]
10. Activation of MET signaling by HDAC6 offers a rationale for a novel ricolinostat and crizotinib combinatorial therapeutic strategy in diffuse large B-cell lymphoma.
Liu Z; Cai Y; Yang Y; Li A; Bi R; Wang L; Shen X; Wang W; Jia Y; Yu B; Cao B; Cui W; Wei P; Zhou X
J Pathol; 2018 Oct; 246(2):141-153. PubMed ID: 29876933
[TBL] [Abstract][Full Text] [Related]
11. Pragmatic recruitment of memantine as the capping group for the design of HDAC inhibitors: A preliminary attempt to unravel the enigma of glioblastoma.
Nepali K; Hsu TI; Hsieh CM; Lo WL; Lai MJ; Hsu KC; Lin TE; Chuang JY; Liou JP
Eur J Med Chem; 2021 May; 217():113338. PubMed ID: 33744690
[TBL] [Abstract][Full Text] [Related]
12. HDAC6 promotes cell proliferation and confers resistance to temozolomide in glioblastoma.
Wang Z; Hu P; Tang F; Lian H; Chen X; Zhang Y; He X; Liu W; Xie C
Cancer Lett; 2016 Aug; 379(1):134-42. PubMed ID: 27267806
[TBL] [Abstract][Full Text] [Related]
13. ACY 1215, a histone deacetylase 6 inhibitor, inhibits cancer cell growth in melanoma.
Wang F; Zhong BW; Zhao ZR
J Biol Regul Homeost Agents; 2018; 32(4):851-858. PubMed ID: 30043566
[TBL] [Abstract][Full Text] [Related]
14. Preclinical activity of combined HDAC and KDM1A inhibition in glioblastoma.
Singh MM; Johnson B; Venkatarayan A; Flores ER; Zhang J; Su X; Barton M; Lang F; Chandra J
Neuro Oncol; 2015 Nov; 17(11):1463-73. PubMed ID: 25795306
[TBL] [Abstract][Full Text] [Related]
15. PTG-0861: A novel HDAC6-selective inhibitor as a therapeutic strategy in acute myeloid leukaemia.
Gawel JM; Shouksmith AE; Raouf YS; Nawar N; Toutah K; Bukhari S; Manaswiyoungkul P; Olaoye OO; Israelian J; Radu TB; Cabral AD; Sina D; Sedighi A; de Araujo ED; Gunning PT
Eur J Med Chem; 2020 Sep; 201():112411. PubMed ID: 32615502
[TBL] [Abstract][Full Text] [Related]
16. A novel HDAC6 inhibitor exerts an anti-cancer effect by triggering cell cycle arrest and apoptosis in gastric cancer.
Dong J; Zheng N; Wang X; Tang C; Yan P; Zhou HB; Huang J
Eur J Pharmacol; 2018 Jun; 828():67-79. PubMed ID: 29563065
[TBL] [Abstract][Full Text] [Related]
17. Design and biological evaluation of tetrahydro-β-carboline derivatives as highly potent histone deacetylase 6 (HDAC6) inhibitors.
Leonhardt M; Sellmer A; Krämer OH; Dove S; Elz S; Kraus B; Beyer M; Mahboobi S
Eur J Med Chem; 2018 May; 152():329-357. PubMed ID: 29738953
[TBL] [Abstract][Full Text] [Related]
18. Krüppel-like factor 9 and histone deacetylase inhibitors synergistically induce cell death in glioblastoma stem-like cells.
Tung B; Ma D; Wang S; Oyinlade O; Laterra J; Ying M; Lv SQ; Wei S; Xia S
BMC Cancer; 2018 Oct; 18(1):1025. PubMed ID: 30348136
[TBL] [Abstract][Full Text] [Related]
19. HDAC4 and HDAC6 sustain DNA double strand break repair and stem-like phenotype by promoting radioresistance in glioblastoma cells.
Marampon F; Megiorni F; Camero S; Crescioli C; McDowell HP; Sferra R; Vetuschi A; Pompili S; Ventura L; De Felice F; Tombolini V; Dominici C; Maggio R; Festuccia C; Gravina GL
Cancer Lett; 2017 Jul; 397():1-11. PubMed ID: 28342984
[TBL] [Abstract][Full Text] [Related]
20. Structure-based design generated novel hydroxamic acid based preferential HDAC6 lead inhibitor with on-target cytotoxic activity against primary choroid plexus carcinoma.
Kassab SE; Mowafy S; Alserw AM; Seliem JA; El-Naggar SM; Omar NN; Awad MM
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1062-1077. PubMed ID: 31072216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
